TL;DR — Vitamin C is essential (humans lack GULO gene → cannot synthesize it), cofactor for collagen hydroxylation, carnitine synthesis, and neurotransmitter synthesis. RDA (75–90 mg) prevents scurvy; longevity-optimizing intake sits at 200–500 mg/day (matches plasma saturation). High-dose IV (Rx, 10–100 g) is a different intervention (pharmacologic effect via H₂O₂ generation, oncology-adjunct research). Standard oral dose 500–1,000 mg/day divided; higher doses just get excreted.
What vitamin C does (and why it matters)
Vitamin C (L-ascorbic acid) is an essential nutrient for humans, chimpanzees, guinea pigs, and a few other species — all of which have inactivating mutations in the GULO (L-gulonolactone oxidase) gene, the final step of endogenous synthesis. Every other mammal makes their own vitamin C from glucose.
Its essential functions: - Cofactor for prolyl and lysyl hydroxylases → collagen crosslinking (why scurvy causes tissue breakdown) - Cofactor for dopamine β-hydroxylase → norepinephrine synthesis - Cofactor for γ-butyrobetaine hydroxylase → carnitine synthesis (from lysine) - Recycles vitamin E from tocopheroxyl radical back to active tocopherol - Direct water-soluble antioxidant at physiologic concentrations
At pharmacologic IV doses (10–100 g/day), vitamin C generates H₂O₂ extracellularly and can act as a pro-oxidant — the basis for ongoing oncology-adjunct research. Oral dosing cannot achieve these concentrations due to saturable intestinal absorption.
Primary hallmarks targeted: Loss of proteostasis (collagen) · Chronic inflammation · Altered intercellular communication (neurotransmitter synthesis)
Padayatty et al. (2004, PMID 15068981) — dose-plasma relationship — oral vitamin C plasma saturates at 200 mg BID (~80 µmol/L); higher oral doses produce diminishing returns and increased urinary loss. Rebouche 1991 — vitamin C required for carnitine synthesis. CHAOS-1 (1996, PMID 8622245) and Physicians' Health Study II (Sesso 2008, PMID 18997197) — long-term antioxidant supplementation with vitamin C alone did not reduce cardiovascular events. Chen et al. (2008, PMID 18678913) — IV ascorbate in cancer: pharmacologic-dose effect on tumor cells via H₂O₂.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Collagen synthesis | Cofactor for prolyl/lysyl hydroxylases | Proteostasis |
| Neurotransmitter synthesis | Dopamine β-hydroxylase → norepinephrine | Communication |
| Carnitine synthesis | Two of four enzymes require ascorbate | Nutrient sensing |
| Vitamin E recycling | Reduces tocopheroxyl radical | Inflammation |
| Iron absorption | Reduces Fe³⁺ → Fe²⁺, enhances non-heme iron absorption | — |
| IV pharmacologic dose | Extracellular H₂O₂ generation (oncology research) | — |
The oral dose ceiling is real: at 200 mg BID, plasma is fully saturated. Higher oral doses (1–2 g) just increase renal excretion and can cause GI upset without meaningful plasma benefit. This is why the "megadose" oral vitamin C strategy for prevention has failed in RCTs.
When vitamin C is worth targeting
Vitamin C is worth optimization when one or more apply:
- Low fruit/vegetable diet (5+ servings covers RDA easily)
- Smoking / chronic oxidative stressAn imbalance between reactive oxygen species (free radicals) produced by metabolism and the antioxidant systems that neutralize them. Full glossary → (higher requirement)
- Recovery from surgery / wounds (collagen synthesis)
- Iron-deficiency anemia (enhances non-heme absorption when co-timed with iron)
- Building a comprehensive antioxidant stack with vitamin E, glutathione
Skip mega-doses — 500–1,000 mg/day divided BID is optimal; higher doses waste money and cause GI issues. IV vitamin C is a separate physician-supervised intervention.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Padayatty 2004 (PMID 15068981) | Pharmacokinetic | Small | Acute | Plasma saturation at 200 mg BID oral | A |
| PHS-II 2008 (PMID 18997197) | RCT (long-term prevention) | 14,641 | 8 yr | No CV benefit with 500 mg/day | A (neg) |
| WACS 2007 (PMID 17698683) | RCT (women CV) | 8,171 | 9.4 yr | No CV benefit in women at high CV risk | A (neg) |
| Cochrane 2013 common cold | Meta | Various | Various | Modest ↓ duration in athletes/cold-exposed; no prevention in general | B |
| Chen 2008 (PMID 18678913) | Preclinical + case series | — | — | IV pharmacologic dose selectively kills cancer cells in vitro | C |
← Swipe for more columns →
Consensus: Tier A for preventing/treating deficiency (scurvy). Tier B for connective tissue support, iron absorption enhancement, and modest cold-duration reduction in athletes. Tier A NEGATIVE for cardiovascular prevention as isolated supplement (PHS-II, WACS). Tier C for pharmacologic IV cancer-adjunct research.
Where oral vitamin C disappoints
- PHS-II and WACS are Tier A NEGATIVE for cardiovascular prevention. Vitamin C alone doesn't reduce CV events in general adult populations. - Prevention of common cold in general population: no effect. Reduces duration in athletes / cold-exposed only. - Kidney stone risk — high-dose vitamin C is metabolized to oxalate, small increase in stone risk in susceptible individuals. - The "megadose to prevent cancer" claim — no oral RCT evidence supports it. IV ascorbate is a different intervention.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Foundation | 500–1,000 mg/day divided BID | Optimal for plasma saturation |
| Smoker / high oxidative stress | 1,000 mg/day | Higher requirement |
| Surgical recovery | 500–1,000 mg TID × 6 weeks | Collagen synthesis support |
| With iron for anemia | 500 mg WITH iron dose | Same meal timing |
| Form | Ascorbic acid or buffered (Ester-C, calcium ascorbate) | Buffered better tolerated at high doses |
| Timing | Divided BID with meals | Half-life ~2h |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Plasma ascorbate | > 50 µmol/L | Not typically needed | Deficiency below 11 µmol/L |
| Wound healing (if surgical use) | Progressing | Weekly | Combine with adequate protein |
| Ferritin (if using with iron) | Rising | 3 months | Combined intervention |
← Swipe for more columns →
Safety, red flags, and contraindications
- Very safe at doses up to 2 g/day.
- GI upset at >2 g/day (osmotic diarrhea).
- Kidney stone risk in susceptible individuals at chronic high dose.
Do not self-start without clearance
- G6PD deficiency — very high-dose IV vitamin C can cause hemolysis.
- Iron overload (hemochromatosis) — enhances non-heme iron absorption; avoid megadose.
- Chronic kidney stone formation — cap at 500 mg/day.
- On chemotherapy — antioxidant interference debated; discuss with oncologist.
- Chronic dialysis — dose adjustment needed.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Vitamin E (mixed tocopherols) | C recycles E from radical form | Antioxidant stack |
| Iron (for absorption) | Enhances non-heme iron uptake | Anemia management |
| Collagen peptides | Vitamin C required for hydroxyproline crosslinking | Skin/joint stack |
| GlutathioneYour body's most abundant internal antioxidant, made from glycine, cysteine, and glutamate. Full glossary → (via GlyNAC) | Complementary redox network | GSH stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Chemotherapy (some regimens) | Antioxidant interference concern | Discuss with oncologist |
| Copper-based supplements (chronic high dose) | Vitamin C can reduce Cu²⁺ absorption long-term | Time apart if both indicated |
| Extreme high oral doses (>10 g/day) | Just excreted; adds GI + stone risk | 500–1,000 mg/day divided is the sweet spot |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.